Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661726 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia
A Phase 2 study, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00661726 is a Phase 2 study that has completed, run by Carelon Research. The registered enrollment target is 6 participants.
The verdict
NCT00661726, a Phase 2 study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Thalassemia intermedia (TI) is an inherited blood disorder that can cause anemia due to low levels of hemoglobin. Decitabine is a medication that may be effective at increasing hemoglobin levels. This study will evaluate the safety and effectiveness of decitabine at increasing hemoglobin levels in people with TI.
Interventions
- DRUG Decitabine (USAN, INN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661726
The ClinicalTrials.gov registry entry for NCT00661726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine (USAN, INN) is the first listed.
NCT00661726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661726 about?
NCT00661726 is a clinical study titled "Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia". Thalassemia intermedia (TI) is an inherited blood disorder that can cause anemia due to low levels of hemoglobin. Decitabine is a medication that may be effective at increasing hemoglobin levels. This study will evaluate the safety and effectiveness of decitabine at increasing hemoglobin levels in p...
What is the current status of trial NCT00661726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00661726?
The interventions under investigation include: Decitabine (USAN, INN) (DRUG).
Who is sponsoring clinical trial NCT00661726?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.